The European Commission approved Johnson and Johnson’s Yuvanci as the first single-pill combination therapy for PAH.
We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving landscape of Alzheimer's treatments.
On Friday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented a post-hoc analysis evaluating the effect of acoramidis on the ...